CME

CME credits: 0.50 Valid until: 07/08/2014 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6757Even though the significant research efforts over the past 40 years have enabled profound changes in the approach and management of patients with advanced melanoma, the prognosis for patients remains poor. The NCI and ACS report that over 75,000 new cases of malignant melanoma were diagnosed in the US in 2011, and over 9,000 patients died from the disease. Melanoma has the fastest-rising incidence of any cancer, with an increase in the US from 1 in 1,500 in 1935 to a rate of 1 in 58 in 2011. Thus the importance of new information coming from a better understanding of molecular targets and inhibitors. Estimated time to complete activity: 30 minutes

CME credits: 0.25 Valid until: 07/02/2014 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6772This CME, case-based activity will provide primary care professionals with tools to optimize outcomes for their patients with chronic musculoskeletal pain. The discussion will specifically address identifying pain types to appropriately select initial treatment options, managing patients who have failed initial medical intervention, and longitudinally managing patients including referral options.

CME credits: 0.25 Valid until: 06/28/2014 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6771Women's healthcare providers play a critical role in educating patients about HPV. In this CME activity, Andrea Singer, MD provides communication and counseling tips to help ensure optimized outcomes for patients at-risk for HPV, and for patients who are HPV-positive. This lecture was recorded live at Omnia Education's Women's Health Annual Visit program directly following an HPV lecture presented by Thomas C. Wright, Jr., MD.

The 2013 ASCO Conference highlighted new advances in the treatment of oncologic malignancies with a focus on targeted therapies and immunotherapies. The age of personalized or "precision" medicine is rapidly advancing with the need for oncologists to better understand the role of genetics and genetic sequencing to optimally implement these new treatment strategies. This ReachMD Project Oncology program features an interview with Dr. Meenhard Herlyn discussing updates on Melanoma cancer presented at the 2013 ASCO conference. 0.25 CME Credits

5-ASA therapy is the foundation of treatment for patients with ulcerative colitis; however, suboptimal dosing and lack of patient adherence are common. This CME interview will discuss identification of first-line 5-ASA treatment as well as 5-ASA therapy's value for patients in whom the benefits diminish over time, and incorporation of established approaches to improving patient adherence and compliance. 0.25 CME Credits

At least 40% of patients treated for chronic pain fail to achieve adequate relief. This interview will focus on managing patients with chronic pain and offer various treatment options to help optimize outcomes. 0.25 CME Credits

CME credits: 0.25 Valid until: 06/25/2014 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=67695-ASA therapy is the foundation of treatment for patients with ulcerative colitis; however, suboptimal dosing and lack of patient adherence are common. This CME interview will discuss identification of first-line 5-ASA treatment as well as 5-ASA therapy's value for patients in whom the benefits diminish over time, and incorporation of established approaches to improving patient adherence and compliance. Share the Ulcerative Colitis Weekly Tips text messaging program with your patients. Click the button below to download a flyer for your office.

CME credits: 0.25 Valid until: 06/21/2014 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6768The 49th Annual ASCO Conference highlighted new advances in the treatment of oncologic malignancies with a focus on targeted therapies and immunotherapies. The age of personalized or "precision" medicine is rapidly advancing with the need for oncologists to better understand the role of genetics and genetic sequencing to optimally implement these new treatment strategies. This ReachMD Project Oncology program features an interview with Dr. Meenhard Herlyn discussing updates on Melanoma cancer presented at the 49th Annual ASCO conference. Estimated time to complete activity: 15 minutes

CME credits: 0.25 Valid until: 06/20/2014 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6730At least 40% of patients treated for chronic pain fail to achieve adequate relief. This interview will focus on managing patients with chronic pain and offer various treatment options to help optimize outcomes.

Shiftwork is a fundamental component of the US workforce, and an integral part of the lifestyles of a large proportion of the population. More than 22 million Americans work on shifts as part of their professional life. According to the Centers for Disease Control and Prevention, shiftwork sleep disorder (SWSD) poses a serious heath burden, because it places patients at an unacceptable risk for developing or exacerbating various comorbid conditions (e.g. cardiovascular disease, diabetes, gastrointestinal problems, depression, etc.), as well as having negative effects on performance, safety, and quality of life. Because many clinicians themselves work extended hours or shifts, they are placing themselves at risk for similar adverse events as their patients. A lack of awareness of the symptoms associated with SWSD, lack of knowledge of management guidelines, and questions regarding the efficacy and safety of management strategies contribute to poor outcomes. Education about SWSD can close the existing knowledge and performance gaps. Increased awareness of the consequences of SWSD can result in enhanced competency and performance among clinicians in recognizing SWSD in their patients, their colleagues and themselves. 0.5 CME Credits

As the second most common hematological malignancy, multiple myeloma has an estimated age-adjusted incidence of 7.5 per 100,000 men and 4.8 per 100,000 women in the U.S. In 2012, it was estimated that there were over 22,300 new cases and over 10,700 deaths attributed to multiple myeloma. Join us and our expert faculty in this challenging patient case as we explore currently available conventional and emergent treatment strategies for managing patients with multiple myeloma as well as the factors that affect induction therapy for transplant- and non-transplant- eligible multiple myeloma patients. 0.25 CME Credits

Shiftwork is a fundamental component of the US workforce, and an integral part of the lifestyles of a large proportion of the population. More than 22 million Americans work on shifts as part of their professional life. According to the Centers for Disease Control and Prevention, shiftwork sleep disorder (SWSD) poses a serious heath burden, because it places patients at an unacceptable risk for developing or exacerbating various comorbid conditions (e.g. cardiovascular disease, diabetes, gastrointestinal problems, depression, etc.), as well as having negative effects on performance, safety, and quality of life. Because many clinicians themselves work extended hours or shifts, they are placing themselves at risk for similar adverse events as their patients. A lack of awareness of the symptoms associated with SWSD, lack of knowledge of management guidelines, and questions regarding the efficacy and safety of management strategies contribute to poor outcomes. Education about SWSD can close the existing knowledge and performance gaps. Increased awareness of the consequences of SWSD can result in enhanced competency and performance among clinicians in recognizing SWSD in their patients, their colleagues and themselves. 0.5 CME Credits

CME credits: 0.50 Valid until: 06/11/2014 Claim your CME credit at http://www.reachmd.com/cmedetails.aspx?sid=6703Shiftwork is a fundamental component of the US workforce, and an integral part of the lifestyles of a large proportion of the population. More than 22 million Americans work on shifts as part of their professional life. According to the Centers for Disease Control and Prevention, shiftwork sleep disorder (SWSD) poses a serious heath burden, because it places patients at an unacceptable risk for developing or exacerbating various comorbid conditions (e.g. cardiovascular disease, diabetes, gastrointestinal problems, depression, etc.), as well as having negative effects on performance, safety, and quality of life. Because many clinicians themselves work extended hours or shifts, they are placing themselves at risk for similar adverse events as their patients. A lack of awareness of the symptoms associated with SWSD, lack of knowledge of management guidelines, and questions regarding the efficacy and safety of management strategies contribute to poor outcomes. Education about SWSD can close the existing knowledge and performance gaps. Increased awareness of the consequences of SWSD can result in enhanced competency and performance among clinicians in recognizing SWSD in their patients, their colleagues and themselves. Estimated time to complete activity: 30 Minutes

The goal of glycemic treatment of patients with type 2 diabetes mellitus (T2DM) is to maintain optimal glycemic control, while causing as few adverse consequences as possible. GLP-1-based therapies represent an important advance in the treatment of T2DM, restoring the diminished incretin effect and potentially addressing the decline in beta-cell function. In addition to their documented effects on glycemic control and weight, GLP-1 therapies are a promising option for ameliorating multiple cardiometabolic risk factors associated with T2DM. Furthermore, once-weekly GLP-1 receptor agonist therapy offers the promise of less frequent dosing with expectations of accompanying improvements in patient compliance and treatment outcomes. Healthcare providers need to have a thorough understanding of the effects of GLP-1-based therapies, particularly in the area of appropriate patient identification and management of potential side effects. 0.5 CME Credits

The goal of glycemic treatment of patients with type 2 diabetes mellitus (T2DM) is to maintain optimal glycemic control, while causing as few adverse consequences as possible. GLP-1-based therapies represent an important advance in the treatment of T2DM, restoring the diminished incretin effect and potentially addressing the decline in beta-cell function. In addition to their documented effects on glycemic control and weight, GLP-1 therapies are a promising option for ameliorating multiple cardiometabolic risk factors associated with T2DM. Furthermore, once-weekly GLP-1 receptor agonist therapy offers the promise of less frequent dosing with expectations of accompanying improvements in patient compliance and treatment outcomes. Healthcare providers need to have a thorough understanding of the effects of GLP-1-based therapies, particularly in the area of appropriate patient identification and management of potential side effects. 0.5 CME Credits